Wall Street brokerages forecast that Voyager Therapeutics (NASDAQ:VYGR) will report $3.17 million in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Voyager Therapeutics’ earnings, with the lowest sales estimate coming in at $1.50 million and the highest estimate coming in at $5.00 million. Voyager Therapeutics reported sales of $1.46 million in the same quarter last year, which indicates a positive year-over-year growth rate of 117.1%. The business is expected to issue its next earnings report on Tuesday, May 8th.
According to Zacks, analysts expect that Voyager Therapeutics will report full year sales of $30.75 million for the current fiscal year, with estimates ranging from $5.00 million to $80.15 million. For the next year, analysts forecast that the firm will post sales of $31.63 million per share, with estimates ranging from $12.00 million to $68.00 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Wednesday, March 14th. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.72) by $0.32. Voyager Therapeutics had a negative net margin of 697.03% and a negative return on equity of 63.18%. The business had revenue of $6.35 million for the quarter, compared to analyst estimates of $5.81 million.
In related news, insider Bernard Ravina sold 2,451 shares of Voyager Therapeutics stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $18.24, for a total transaction of $44,706.24. Following the completion of the transaction, the insider now directly owns 4,902 shares of the company’s stock, valued at approximately $89,412.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Dinah Ph.D. Sah sold 15,623 shares of Voyager Therapeutics stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $30.00, for a total transaction of $468,690.00. Following the transaction, the insider now directly owns 140,872 shares of the company’s stock, valued at $4,226,160. The disclosure for this sale can be found here. Insiders have sold a total of 66,908 shares of company stock valued at $1,574,258 over the last three months. 8.00% of the stock is currently owned by insiders.
A number of hedge funds have recently made changes to their positions in VYGR. State Street Corp lifted its holdings in Voyager Therapeutics by 11.8% during the 2nd quarter. State Street Corp now owns 184,526 shares of the company’s stock valued at $1,653,000 after purchasing an additional 19,471 shares during the last quarter. California State Teachers Retirement System lifted its holdings in Voyager Therapeutics by 8.4% during the 2nd quarter. California State Teachers Retirement System now owns 25,811 shares of the company’s stock valued at $231,000 after purchasing an additional 2,000 shares during the last quarter. Nationwide Fund Advisors lifted its holdings in Voyager Therapeutics by 81.5% during the 3rd quarter. Nationwide Fund Advisors now owns 19,779 shares of the company’s stock valued at $407,000 after purchasing an additional 8,884 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of Voyager Therapeutics by 16.2% in the third quarter. Bank of New York Mellon Corp now owns 61,858 shares of the company’s stock worth $1,274,000 after acquiring an additional 8,633 shares during the last quarter. Finally, JPMorgan Chase & Co. bought a new position in shares of Voyager Therapeutics in the third quarter worth about $270,000. 78.22% of the stock is owned by hedge funds and other institutional investors.
Shares of Voyager Therapeutics stock traded up $0.68 during trading on Wednesday, hitting $18.53. 647,500 shares of the company’s stock traded hands, compared to its average volume of 333,381. Voyager Therapeutics has a twelve month low of $8.10 and a twelve month high of $31.91. The firm has a market cap of $574.89, a P/E ratio of -7.02 and a beta of 2.97.
WARNING: This news story was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://stocknewstimes.com/2018/04/21/voyager-therapeutics-vygr-expected-to-announce-quarterly-sales-of-3-17-million.html.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.